OncoMatch/Clinical Trials/NCT07151391
The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)
Is NCT07151391 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Guarana for neuroendocrine tumors.
Treatment: Guarana — The purpose of this clinical trial is to learn if the drug guarana improves symptoms of fatigue in patients with neuroendocrine tumors and gynecologic cancers
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Neuroendocrine Tumor
Ovarian Cancer
Endometrial Cancer
Cervical Cancer
Disease stage
Required: Stage III, IV, I, II
unresected locally advanced or metastatic well differentiated neuroendocrine tumors; early-stage (I or II) ovarian/fallopian-tube cancer; endometrial cancer which is low risk, low-intermediate risk in surveillance, or high-intermediate risk receiving brachytherapy
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: cytotoxic chemotherapy
Receiving treatment with Cytotoxic Chemotherapy, Radiation Therapy, PRRT or TKIs within 6 weeks prior to the first dose of study treatment
Cannot have received: radiation therapy
Receiving treatment with Cytotoxic Chemotherapy, Radiation Therapy, PRRT or TKIs within 6 weeks prior to the first dose of study treatment
Cannot have received: PRRT
Receiving treatment with Cytotoxic Chemotherapy, Radiation Therapy, PRRT or TKIs within 6 weeks prior to the first dose of study treatment
Cannot have received: tyrosine kinase inhibitor
Receiving treatment with Cytotoxic Chemotherapy, Radiation Therapy, PRRT or TKIs within 6 weeks prior to the first dose of study treatment
Lab requirements
Blood counts
Hemoglobin ≥ 9 g/dL
Kidney function
Estimated creatinine clearance ≥ 30 mL/min by Cockcroft-Gault formula
Liver function
Total Bilirubin ≤ 1.5x institutional ULN or ≤3 x ULN with documented liver involvement and/or Gilbert's disease; AST(SGOT)/ALT(SGPT) ≤ 3 × institutional ULN; Subjects with liver metastases will be allowed to enroll with AST and ALT levels ≤ 5 x ULN.
Adequate organ function as defined as: Hematologic: Hemoglobin ≥ 9 g/dL; Hepatic: Total Bilirubin ≤ 1.5x institutional ULN or ≤3 x ULN with documented liver involvement and/or Gilbert's disease; AST(SGOT)/ALT(SGPT) ≤ 3 × institutional ULN; Subjects with liver metastases will be allowed to enroll with AST and ALT levels ≤ 5 x ULN. Renal: Estimated creatinine clearance ≥ 30 mL/min by Cockcroft-Gault formula
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Huntsman Cancer Institute at University of Utah · Salt Lake City, Utah
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07151391 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior cytotoxic chemotherapy, radiation therapy, PRRT disqualifies patients from enrollment.
What disease stage is eligible?
Stage III or IV or I or II is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages